Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

Experts discuss how institutions can develop standardized operational workflows that accommodate multiple bispecific products with different administration requirements, particularly as more products become available.

EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care

EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies

EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

Now Viewing

EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

EP: 9.Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

EP: 10.Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

EP: 11.Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

EP: 12.Payer and Reimbursement Considerations for Bispecific Therapies

EP: 13.Emerging Therapeutic Areas for Bispecific Antibodies

EP: 14.Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

EP: 15.Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

How can institutions develop standardized operational workflows that accommodate multiple bispecific products with different administration requirements, particularly as more products become available?

Related Videos

Related Content

Advertisement

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 7th 2025

Cases Show How Epcoritamab Revived CAR T Cells After Relapse in DLBCL

Mary Caffrey

July 7th 2025

The Rise of Precision Monoclonal Antibodies in Treating MS

Skylar Jeremias

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

Related Content

Advertisement

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 8th 2025

Corticosteroid Premedication for Infliximab Remains Unnecessarily Common

Shirley Cohen-Mekelburg, MD, MS Jeffrey Gibbs, MD Beth Wallace, MD, MS Brooke Kenney, MPH Akbar K. Waljee, MD, MSc

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 7th 2025

Cases Show How Epcoritamab Revived CAR T Cells After Relapse in DLBCL

Mary Caffrey

July 7th 2025

The Rise of Precision Monoclonal Antibodies in Treating MS

Skylar Jeremias

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.